AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3539462 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 9
Study 31403815 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 4 Health (G4H)
Number of subjects: 120
Study 29283674 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended educational experience with video narratives and direct interactions with people affected by IDD
Number of subjects: 27
Study 29283674 — intervention group
Group type: COMPARATOR
Intervention: Introductory video lecture about IDD healthcare
Number of subjects: 27
Study 27349621 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERACT quality improvement program
Number of subjects: 64
Study 27349621 — intervention group
Group type: COMPARATOR
Intervention: Transfers within 48 hours or 30 days
Number of subjects: 64
Study 25580060 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg/day for 6 months)
Number of subjects: 52
Study 22467928 — intervention group
Group type: EXPERIMENTAL
Intervention: MACTAR
Number of subjects: 192
Study 19890266 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (10 mg)
Number of subjects: 159
Study 19890266 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (20 mg)
Number of subjects: 159
Study 19890266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 18831930 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled thiamphenicol associated with acetylcysteine (250 mg: 1/2 vial in the morning and 1/2 vial in the evening) for 5 days (Group A)
Number of subjects: 90
Study 18831930 — intervention group
Group type: COMPARATOR
Intervention: Saline solution twice daily for 5 days (Group B)
Number of subjects: 90
Study 15838660 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A: Docetaxel 60 mg/m² over 1 hour followed by Topotecan 0.85 mg/m² continuous infusion over 72 hours
Number of subjects: 30
Study 15838660 — intervention group
Group type: COMPARATOR
Intervention: Schedule B: Topotecan 0.85 mg/m² continuous infusion over 72 hours followed by Docetaxel 60 mg/m² over 1 hour
Number of subjects: 30
Study 15838660 — intervention group
Group type: EXPERIMENTAL
Intervention: Schedule A
Number of subjects: 30
Study 15838660 — intervention group
Group type: COMPARATOR
Intervention: Schedule B
Number of subjects: 30
Study 11866182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes
Number of subjects: 0
Study 11866182 — intervention group
Group type: COMPARATOR
Intervention: De‐nicotinized cigarettes
Number of subjects: 0
Study 11866182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine instructions
Number of subjects: 0
Study 11866182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes or instructions indicating nicotine content
Number of subjects: 0
Study 10517908 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral diltiazem
Number of subjects: 30
Study 10517908 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily diltiazem
Number of subjects: 30
Study 10517908 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily diltiazem
Number of subjects: 30
Study 10517908 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diltiazem gel
Number of subjects: 30
Study 10517908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bethanechol gel
Number of subjects: 30
Study 7563935 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 64
Study 7563935 — intervention group
Group type: COMPARATOR
Intervention: Non-G-CSF
Number of subjects: 64
Study 1891681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aerosol (400 micrograms once daily)
Number of subjects: 60
Study 1891681 — intervention group
Group type: COMPARATOR
Intervention: Budesonide dry powder (400 micrograms once daily)
Number of subjects: 60
Study 6337323 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective environment
Number of subjects: 130
Study 6337323 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately severe to severe acute GVHD
Number of subjects: 130
Study 6337323 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractoriness to random-donor platelet infusions at transplantation
Number of subjects: 130
Study 6337323 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 130
Study 6337323 — intervention group
Group type: COMPARATOR
Intervention: Acute or chronic graft-versus-host disease (GVHD)
Number of subjects: 130
Study 30745097 — intervention group
Group type: EXPERIMENTAL
Intervention: NIT+IPC (NO3‐‐rich gel ingested 90min prior to testing)
Number of subjects: 10
Study 30745097 — intervention group
Group type: COMPARATOR
Intervention: PLA+IPC (low NO3‐ placebo ingested 90min prior to testing)
Number of subjects: 10
Study 30745097 — intervention group
Group type: COMPARATOR
Intervention: BASE (no dietary intervention or IPC)
Number of subjects: 10
Study 30081338 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief therapy (BT)
Number of subjects: 290
Study 30081338 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release injectable naltrexone (XR-NTX)
Number of subjects: 290
Study 30081338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BT and XR-NTX
Number of subjects: 290
Study 30081338 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, white race, talking with a professional about alcohol use, and having more negative consequences
Number of subjects: 290
Study 30081338 — intervention group
Group type: EXPERIMENTAL
Intervention: Not being homeless and previously talking with a professional
Number of subjects: 290
Study 30081338 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, white race, and experiencing more negative consequences
Number of subjects: 290
Study 30081338 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of BT preceding XR-NTX
Number of subjects: 290
Study 27068751 — intervention group
Group type: COMPARATOR
Intervention: Booklet
Number of subjects: 312
Study 27068751 — intervention group
Group type: COMPARATOR
Intervention: Combined
Number of subjects: 312
Study 27068751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 312
Study 25226881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11140
Study 25226881 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study 23042313 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 185
Study 23042313 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) therapy
Number of subjects: 185
Study 19409546 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (three coagulation points per ovary)
Number of subjects: 80
Study 19409546 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (four to five coagulation points per ovary)
Number of subjects: 80
Study 19409546 — intervention group
Group type: COMPARATOR
Intervention: Group A (one coagulation point per ovary)
Number of subjects: 80
Study 19409546 — intervention group
Group type: COMPARATOR
Intervention: Group B (two coagulation points per ovary)
Number of subjects: 80
Study 18565887 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy with temozolomide (n = 42)
Number of subjects: 80
Study 18565887 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy with temozolomide
Number of subjects: 80
Study 15997317 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccines (WHO‐17D and Brazilian 17DD substrains)
Number of subjects: 1087
Study 15997317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1087
Study 11893094 — intervention group
Group type: EXPERIMENTAL
Intervention: DB+AD
Number of subjects: 169
Study 11893094 — intervention group
Group type: COMPARATOR
Intervention: DB-only
Number of subjects: 169
Study 10051263 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1,000 mg)
Number of subjects: 30
Study 10051263 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1,000 mg)
Number of subjects: 30
Study 10051263 — intervention group
Group type: COMPARATOR
Intervention: LPS (4 ng/kg)
Number of subjects: 30
Study 8808181 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 micrograms of formoterol (F6)
Number of subjects: 18
Study 8808181 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms of formoterol (F12)
Number of subjects: 18
Study 8808181 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms of formoterol (F24)
Number of subjects: 18
Study 8808181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 1851065 — intervention group
Group type: EXPERIMENTAL
Intervention: Borg scale estimates of breathlessness
Number of subjects: 0
Study 7006441 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine 0.5% (mean dose 112.8 mg)
Number of subjects: 93
Study 7006441 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (mean dose 200 mg) and inhalational analgesia
Number of subjects: 93
Study 7006441 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 93
Study 7006441 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia and Pethidine
Number of subjects: 93
Study 31151474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 31151474 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 28835192 — intervention group
Group type: EXPERIMENTAL
Intervention: Active flexion added to modified Kleinert regime
Number of subjects: 53
Study 28835192 — intervention group
Group type: COMPARATOR
Intervention: Modified Kleinert regime
Number of subjects: 53
Study 25147125 — intervention group
Group type: EXPERIMENTAL
Intervention: Water intake during meals
Number of subjects: 28
Study 25147125 — intervention group
Group type: COMPARATOR
Intervention: No water intake during meals
Number of subjects: 28
Study 23380214 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral Meridian (CM) therapy
Number of subjects: 28
Study 23380214 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 22878599 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest autograft
Number of subjects: 354
Study 22878599 — intervention group
Group type: COMPARATOR
Intervention: No iliac crest autograft (Control)
Number of subjects: 354
Study 20353746 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release formulation of diltiazem hydrochloride (240 mg dose)
Number of subjects: 0
Study 20353746 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation 3
Number of subjects: 0
Study 20353746 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation with highest amount of polysaccharide in coating
Number of subjects: 0
Study 17937084 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (performed biweekly from day 5 of the follicular phase through the luteal phase, not on the day of embryo transfer)
Number of subjects: 32
Study 17937084 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched according to age, previous failed IVF cycles, and type of embryo transfer)
Number of subjects: 32
Study 15890735 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed hCG administration (late-hCG group, n = 5)
Number of subjects: 10
Study 15890735 — intervention group
Group type: COMPARATOR
Intervention: Early hCG administration (early-hCG group, n = 5)
Number of subjects: 10
Study 12235246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of oral folic acid for 6 weeks
Number of subjects: 27
Study 12235246 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects with below-median tHcy reduction)
Number of subjects: 27
Study 9440742 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel monotherapy
Number of subjects: 936
Study 7674104 — intervention group
Group type: EXPERIMENTAL
Intervention: ST waveform + CTG
Number of subjects: 2400
Study 7674104 — intervention group
Group type: COMPARATOR
Intervention: CTG only
Number of subjects: 2400
Study 3289398 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (2.5 mg)
Number of subjects: 118
Study 3289398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 29884144 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific computerized training (ST)
Number of subjects: 36
Study 29884144 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific computerized training (nST)
Number of subjects: 36
Study 25942419 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Inertial Eccentric Overload and Vibration Training (EVT)
Number of subjects: 24
Study 25942419 — intervention group
Group type: COMPARATOR
Intervention: Conventional combined training (CONV)
Number of subjects: 24
Study 25682273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 65
Study 25682273 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 65
Study 23263970 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual 24% sucrose (1 ml) administered 2 min before OGT insertion
Number of subjects: 60
Study 23263970 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (1 ml) administered 2 min before OGT insertion (Placebo)
Number of subjects: 60
Study 20797477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented red pepper paste (FRPP)
Number of subjects: 28
Study 20797477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18298562 — intervention group
Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 88
Study 18298562 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 88
Study 18298562 — intervention group
Group type: EXPERIMENTAL
Intervention: PET and/or PET/CT
Number of subjects: 88
Study 15925045 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of 50 microg misoprostol (n=100)
Number of subjects: 600
Study 15925045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induction (n=100)
Number of subjects: 600
Study 15925045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical insertion of a Foley balloon (n=100)
Number of subjects: 600
Study 15925045 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous follow-up (n=300)
Number of subjects: 600
Study 14586050 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma nurse follow-up
Number of subjects: 74
Study 14586050 — intervention group
Group type: COMPARATOR
Intervention: Paediatrician follow-up
Number of subjects: 74
Study 9862846 — intervention group
Group type: EXPERIMENTAL
Intervention: trapidil (400 mg/d) and ticlopidine (250 mg/d)
Number of subjects: 90
Study 9862846 — intervention group
Group type: COMPARATOR
Intervention: heparin treatment (12 to 24 U/kg bolus, 1 week intravenous, 4 weeks subcutaneous)
Number of subjects: 90
Study 9295485 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 51
Study 9295485 — intervention group
Group type: COMPARATOR
Intervention: Preoperative instruction only (Control)
Number of subjects: 51
Study 2070507 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of the second questionnaire after the 8-month assessment
Number of subjects: 0
Study 2070507 — intervention group
Group type: COMPARATOR
Intervention: Completion of the second questionnaire before the assessment
Number of subjects: 0
Study 2070507 — intervention group
Group type: EXPERIMENTAL
Intervention: Health visitor assessment at 8 months
Number of subjects: 0
Study 6840954 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum-cholesterol-lowering (SCL) diet, low in saturated fats and cholesterol, high in poly-unsaturated fats
Number of subjects: 0
Study 6840954 — intervention group
Group type: COMPARATOR
Intervention: Normal hospital diet
Number of subjects: 0
Study 29261824 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate, 1mg twice daily for 16 weeks
Number of subjects: 131
Study 26875901 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary bypass grafting by small incision at the left chest
Number of subjects: 201
Study 26875901 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass grafting by extracorporeal circulation
Number of subjects: 201
Study 25377361 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 99
Study 25377361 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 99
Study 25377361 — intervention group
Group type: COMPARATOR
Intervention: Sham maneuver
Number of subjects: 99
Study 22549506 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Pneumatic Compression Device (APCD) - Flexitouch system, HCPCS E0652
Number of subjects: 36
Study 22549506 — intervention group
Group type: COMPARATOR
Intervention: Standard Pneumatic Compression Device (SPCD) - Bio Compression 2004, HCPCS E0651
Number of subjects: 36
Study 19230767 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI meal (1 g kg(‐1) body mass of carbohydrate, consumed 45 min prior to TT)
Number of subjects: 10
Study 19230767 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI meal
Number of subjects: 10
Study 19230767 — intervention group
Group type: COMPARATOR
Intervention: High GI meal
Number of subjects: 10
Study 17244135 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramid-based education with a full-time nurse educator for care-aides
Number of subjects: 14
Study 17244135 — intervention group
Group type: COMPARATOR
Intervention: Seminar with a dental hygienist for care-aides (control group)
Number of subjects: 14
Study 15124260 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood at baseline
Number of subjects: 57
Study 11584093 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodized oil supplementation
Number of subjects: 0
Study 11584093 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented group (placebo)
Number of subjects: 0
Study 9428853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl Oralet (10-15 micrograms/kg)
Number of subjects: 40
Study 9428853 — intervention group
Group type: COMPARATOR
Intervention: Control (candy matrix)
Number of subjects: 40
Study 9428853 — intervention group
Group type: COMPARATOR
Intervention: Control (i.v. fentanyl 2 micrograms/kg)
Number of subjects: 40
Study 7719946 — intervention group
Group type: EXPERIMENTAL
Intervention: Various pharmacologic agents used in the treatment of CHF, specific dosages and durations not mentioned.
Number of subjects: 0
Study 7719946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies for CHF, specific agents not mentioned.
Number of subjects: 0
Study 2540005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30
Study 2540005 — intervention group
Group type: COMPARATOR
Intervention: ACTH
Number of subjects: 30
Study 2540005 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 30
Study 2540005 — intervention group
Group type: COMPARATOR
Intervention: Control (CSF and neurophysiological parameters)
Number of subjects: 30
Study 1007937 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral, non-dominant ECT with four treatments weekly
Number of subjects: 103
Study 1007937 — intervention group
Group type: COMPARATOR
Intervention: Unilateral, non-dominant ECT with two treatments weekly
Number of subjects: 103
Study 30004111 — intervention group
Group type: EXPERIMENTAL
Intervention: DEFA5 rs4415345 G vs. C
Number of subjects: 443
Study 30004111 — intervention group
Group type: EXPERIMENTAL
Intervention: DEFA5 rs4610776 T vs. A
Number of subjects: 443
Study 30004111 — intervention group
Group type: EXPERIMENTAL
Intervention: REG3A SNP
Number of subjects: 443
Study 26936722 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase aberration correction
Number of subjects: 4
Study 26936722 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected phase aberration
Number of subjects: 4
Study 24715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Granule (LDG) given for 3 menstrual cycles before IVF
Number of subjects: 66
Study 24715425 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Granule (LDG)
Number of subjects: 66
Study 24715425 — intervention group
Group type: COMPARATOR
Intervention: Placebo granule
Number of subjects: 66
Study 23392652 — intervention group
Group type: EXPERIMENTAL
Intervention: Fake video or photograph of cheating shown after a 9‐min delay (Experiment 1)
Number of subjects: 0
Study 23392652 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated false evidence over time (Experiment 2)
Number of subjects: 0
Study 23392652 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21155012 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11‐containing combination chemotherapy
Number of subjects: 657
Study 18227526 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (DA) 6.75 microg/kg every 4 weeks for up to 16 weeks
Number of subjects: 0
Study 18227526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18227526 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (DA)
Number of subjects: 0
Study 15099661 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction intervention focusing on safer injection and sex behaviors
Number of subjects: 577
Study 15099661 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing addressing lifestyle changes including drug treatment
Number of subjects: 577
Study 15099661 — intervention group
Group type: EXPERIMENTAL
Intervention: Free treatment (coupon for 90 days)
Number of subjects: 577
Study 15099661 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing
Number of subjects: 577
Study 12369794 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day)
Number of subjects: 90
Study 12369794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone-replacement therapy (HRT; 1 mg of 17beta-estradiol combined with 0.5 mg of norethisterone acetate)
Number of subjects: 90
Study 12369794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 10326110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm infection
Number of subjects: 729
Study 10326110 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria parasitaemia
Number of subjects: 729
Study 10326110 — intervention group
Group type: EXPERIMENTAL
Intervention: S. mansoni infection
Number of subjects: 729
Study 10326110 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 729
Study 7790678 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 0